Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury
Linnéa Lagerstedt; Leire Azurmendi; Olli Tenovuo; Ari J. Katila; Riikka S. K. Takala; Kaj Blennow; Virginia F. J. Newcombe; Henna-Riikka Maanpää; Jussi Tallus; Iftakher Hossain; Mark van Gils; David K. Menon; Peter J. Hutchinson; Henrik Zetterberg; Jussi P. Posti; Jean-Charles Sanchez
Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury
Linnéa Lagerstedt
Leire Azurmendi
Olli Tenovuo
Ari J. Katila
Riikka S. K. Takala
Kaj Blennow
Virginia F. J. Newcombe
Henna-Riikka Maanpää
Jussi Tallus
Iftakher Hossain
Mark van Gils
David K. Menon
Peter J. Hutchinson
Henrik Zetterberg
Jussi P. Posti
Jean-Charles Sanchez
FRONTIERS MEDIA SA
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042825326
https://urn.fi/URN:NBN:fi-fe2021042825326
Tiivistelmä
Background:Patients with traumatic brain injury (TBI) exhibit a variable and unpredictable outcome. The proteins interleukin 10 (IL-10) and heart fatty acid-binding protein (H-FABP) have shown predictive values for the presence of intracranial lesions. Aim:To evaluate the individual and combined outcome prediction ability of IL-10 and H-FABP, and to compare them to the more studied proteins S100 beta, glial fibrillary acidic protein (GFAP), and neurofilament light (NF-L), both with and without clinical predictors. Methods:Blood samples from patients with acute TBI (all severities) were collected 6 months post injury using the Glasgow Outcome Scale Extended (GOSE) score, dichotomizing patients into: (i) those with favorable (GOSE >= 5)/unfavorable outcome (GOSE <= 4) and complete (GOSE = 8)/incomplete (GOSE <= 7) recovery, and (ii) patients with mild TBI (mTBI) and patients with TBIs of all severities. Results:When sensitivity was set at 95-100%, the proteins' individual specificities remained low. H-FABP showed the best specificity (%) and sensitivity (100%) in predicting complete recovery in patients with mTBI. IL-10 had the best specificity (50%) and sensitivity (96%) in identifying patients with favorable outcome in patients with TBIs of all severities. When individual proteins were combined with clinical parameters, a model including H-FABP, NF-L, and ISS yielded a specificity of 56% and a sensitivity of 96% in predicting complete recovery in patients with mTBI. In predicting favorable outcome, a model consisting IL-10, age, and TBI severity reached a specificity of 80% and a sensitivity of 96% in patients with TBIs of all severities. Conclusion:Combining novel TBI biomarkers H-FABP and IL-10 with GFAP, NF-L and S100 beta and clinical parameters improves outcome prediction models in TBI.
Kokoelmat
- Rinnakkaistallenteet [29335]
